National Psoriasis Foundation Awards ZORYVE Seal of Recognition

Key Takeaways

• The National Psoriasis Foundation (NPF) has expanded its Seal of Recognition to include FDA-approved prescription products.

• Arcutis’ ZORYVE (roflumilast) cream and foam 0.3% are the first prescription treatments to receive the designation.

The National Psoriasis Foundation (NPF) awarded its first Seal of Recognition to ZORYVE® (roflumilast) cream and foam 0.3%, according to a press release from the Foundation. 

The NPF Seal of Recognition, according to the organization, helps patients and clinicians identify non-irritating products safe for use on psoriatic skin or joints. The designation was previously limited to personal care and over-the-counter items. The expansionthe reflects a broader view of therapeutic options available to individuals managing psoriatic disease, according to the news release. 

“The NPF Seal of Recognition is awarded to products that meet our rigorous standards for people living with psoriasis or psoriatic arthritis,” said Leah M. Howard, JD, president and CEO of the NPF, in the release. “We are pleased to expand our directory beyond over-the-counter items to recognize FDA-approved treatments like this one. It is great for our community to have multiple formulations that are suitable for sensitive and hard-to-treat areas. This reflects real progress in addressing the daily needs of people with psoriasis.”

Arcutis’ President and CEO Frank Watanabe described the award as a milestone in the company’s mission to develop non-steroidal, long-term topical therapies.

“It is a tremendous honor that ZORYVE is the first FDA-approved product to receive the NPF Seal of Recognition,” said Watanabe in the press release. “With cream and foam formulations, ZORYVE offers individuals with psoriasis and their physicians a choice...with no limitation on duration of use. This recognition reinforces our commitment to developing innovative therapies that meet the real-world needs of people with chronic inflammatory skin diseases.”

Source: NPF news release. June 2, 2025.